A philanthropist is paying for the rapamycin trial no drug company would fund

Every argument about rapamycin as an anti-ageing drug eventually runs into the same wall. The laboratory evidence is strong and the human evidence is thin, and the reason it is thin is not scientific. Rapamycin is generic. No company owns it, so no company has a commercial reason to spend tens of millions of dollars proving what it does over years in healthy people [s3].

The University of Arizona has found a way round that. In March its R. Ken Coit College of Pharmacy announced a double-blind, randomised phase 3 trial of low-dose rapamycin in adults aged 65 and over, funded with $12 million in philanthropic support from the alumnus the college is named for [s1].

What it is designed to measure

The design matters more than the money, because it is the first rapamycin study in healthy ageing built around something that happens to a person rather than something that happens in a blood tube.

Participants will be randomised to rapamycin or placebo for two years, with an additional year of follow-up, and the trial as a whole is projected to take six years pending final approval from the US Food and Drug Administration [s1]. There are two main measures. The first is physical function — specifically whether rapamycin changes the transition to frailty. The second is the level of interleukin-6, an inflammatory marker associated with many age-related diseases including frailty [s1].

Frailty transition is an outcome. It is a state a person moves into, it changes what they can do, and it does not require anyone to accept a theory about what a molecular measurement stands for. That is a meaningfully different thing to test than the endpoints previous rapamycin studies have used.

The distinction matters because the whole geroscience field runs on a workaround. Nobody can wait out a lifespan, so trials substitute a marker that moves inside a few years and hope it stands in for the thing that takes decades. The substitution is only as good as the evidence that the marker tracks the outcome — evidence that, for most candidate ageing biomarkers, does not yet exist. A trial that counts how many people become frail sidesteps the problem rather than betting on it. The interleukin-6 arm of the design still rests on a biomarker, but it is being asked alongside a functional measure rather than in place of one [s1].

Why the existing evidence could not answer this

The largest and longest trial to date, PEARL, ran for 48 weeks in adults aged 50 to 85 and used visceral fat measured by DXA scan as its primary endpoint [s2]. Visceral fat did not change significantly, at a partial eta squared of 0.001 and p = 0.942 [s2]. The trial's positive results were confined to secondary and exploratory measures in small subgroups — most prominently lean tissue mass in women taking the higher dose, where the confidence interval around the odds ratio ran from 2.42 to 323.7 [s2].

Across the wider literature the picture is the same. A 2025 review of low-dose rapamycin and rapalog therapy in healthy adults counted fewer than a dozen trials, exploring immune function, protein synthesis and haematological parameters, and concluded that human data have yet to establish rapamycin as a proven therapy that delays ageing in healthy older adults [s3]. Two years of dosing against placebo with a frailty endpoint is a different order of evidence.

The dosing question underneath it

There is a mechanistic reason the field keeps returning to intermittent dosing. Rapamycin inhibits two protein complexes, and the working model is that inhibiting the first, mTORC1, is what promotes healthy ageing, while many of the drug's unwanted effects — immunosuppression and metabolic disruption — track with inhibition of the second, mTORC2 [s4]. Because the two complexes are inhibited with different kinetics, the argument runs, an intermittent schedule might hit one and largely spare the other [s4].

That is a hypothesis, not a finding. As a researcher running two of the ongoing human trials put it in a 2025 conference abstract, the optimal dosing schedules and the long-term efficacy of such interventions in humans are unknown, and it also remains unknown how different rapamycin schedules interact with the health benefits of exercise [s4]. An increasing number of physically active adults are taking rapamycin off-label anyway [s4].

What to watch

Three things will determine whether this trial is worth the six years.

Whether it enrols the people the question is about. Previous rapamycin cohorts have skewed health-conscious and male — PEARL's was 35.1% women [s2] — which is close to the worst case for detecting an effect on functional decline.

Whether frailty transition proves measurable on this timescale. Two years of dosing is long by the standards of this field and short by the standards of ageing.

And whether the safety record holds at continuous weekly exposure. PEARL found adverse events essentially matched between arms over 48 weeks, with 117, 116 and 122 non-serious events in the 10 mg, 5 mg and placebo groups [s2]. A larger and older cohort dosed for more than twice as long is a genuinely different safety question, and the trial has not started reporting.

Rapamycin remains a prescription immunosuppressant used off-label for ageing. Nothing here is medical advice, and no dose described in this article should be read as guidance.

Sources

1. [s1] U of A launches rapamycin clinical trial with philanthropic support of alumnus Ken Coit. University of Arizona News, March 30, 2026. https://news.arizona.edu/news/u-launches-rapamycin-clinical-trial-philanthropic-support-alumnus-ken-coit
2. [s2] Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY), published online April 4, 2025. https://doi.org/10.18632/aging.206235
3. [s3] What is the clinical evidence to support off-label rapamycin therapy in healthy adults? Aging (Albany NY), published online August 7, 2025. https://doi.org/10.18632/aging.206300
4. [s4] Testing the Translational Potential of Rapamycin on Healthy Aging. Innovation in Aging, published online December 31, 2025. https://doi.org/10.1093/geroni/igaf122.406